Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1016/j.surge.2019.11.005

Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?

..., Alexander G. Heriot
48
Volume: 18, Issue: 5, Pages: 287 - 294
Published: Oct 1, 2020
Abstract
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers selected patients with peritoneal surface malignancies (PSM) an improved survival. However, a substantial proportion of patients develop peritoneal recurrence. There is limited data on the efficacy of iterative CRS and HIPEC in such patients. This study evaluates the safety, efficacy and outcomes after re-do CRS and HIPEC for PSM at a tertiary institute....
Paper Fields
Paper Details
Title
Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
DOI
doi.org/10.1016/j.surge.2019.11.005
Published Date
Oct 1, 2020
Volume
18
Issue
5
Pages
287 - 294
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.